The exact window for stopping and restarting semaglutide can vary based on the type of surgery, anesthesia used, and your overall health
To find out if this option is right for you, consult with your healthcare professional
Liraglutide, semaglutide and tirzepatide are incretin-based therapies currently approved by FDA for the management of obesity, while triple GIPR/GCGR/GLP-1R agonist retatrutide (LY3437943), the cagrilintide/semaglutide (CagriSema) 2.4 mg combination, high-dose oral semaglutide, and oral orforglipron are in advanced stages of development
Even partial degradation means you are paying full price for reduced effectiveness
Within this class of medications, there are two alternatives to Wegovy that are FDA approved for weight loss: Saxenda (liraglutide) and Zepbound (tirzepatide)